Financhill
Sell
20

CLLKF Quote, Financials, Valuation and Earnings

Last price:
$2.21
Seasonality move :
15.9%
Day range:
$2.21 - $2.21
52-week range:
$2.00 - $4.21
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.95x
P/B ratio:
0.81x
Volume:
--
Avg. volume:
365
1-year change:
-21.24%
Market cap:
$155.9M
Revenue:
$184.1M
EPS (TTM):
-$1.04

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Downside
    No price target exists because of limited analyst coverage.
  • Price Target Upside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, BICO Group AB has -- downside to fair value with a price target of -- per share.

CLLKF vs. S&P 500

  • Over the past 5 trading days, BICO Group AB has overperformed the S&P 500 by 0.05% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • BICO Group AB does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • BICO Group AB has grown year-over-year revenues for 1 quarter straight. In the most recent quarter BICO Group AB reported revenues of $40.7M.

Earnings Growth

  • BICO Group AB earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter BICO Group AB reported earnings per share of -$0.91.
Enterprise value:
162M
EV / Invested capital:
0.49x
Price / LTM sales:
0.95x
EV / EBIT:
25.34x
EV / Revenue:
0.99x
PEG ratio (5yr expected):
-0.18x
EV / Free cash flow:
10.79x
Price / Operating cash flow:
10.38x
Enterprise value / EBITDA:
35.35x
Gross Profit (TTM):
$72.4M
Return On Assets:
-27.96%
Net Income Margin (TTM):
-81.48%
Return On Equity:
-52.81%
Return On Invested Capital:
-32.69%
Operating Margin:
-7.57%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue $214.2M $157.5M $163.6M $35.4M $40.7M
Gross Profit $47.3M $49.3M $72.4M $12.7M $17.4M
Operating Income -$38.6M -$41.3M -$23.1M -$6.4M -$3.1M
EBITDA -$4.1M -$8.7M $4.6M $220.7K $2.4M
Diluted EPS -$2.10 -$1.22 -$1.04 -$0.33 -$0.91
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $215M $195.5M $185.7M $167.1M $208.2M
Total Assets $775.5M $972.3M $605.9M $539.7M $398M
Current Liabilities $56.5M $94.1M $77.7M $59.6M $163M
Total Liabilities $269.7M $308.9M $269.5M $266.3M $205.4M
Total Equity $505.8M $663.5M $336.4M $273.4M $192.6M
Total Debt $178.4M $165.4M $170.4M $189.4M $31.8M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations -$4.6M $13M $18.7M $4.2M -$3.2M
Cash From Investing -$25M $8.8M $95.1M -$2.8M $75.2M
Cash From Financing $37.3M -$10.6M -$58.5M -$1.9M -$12.6M
Free Cash Flow -$39.4M $4M $15M $1.4M -$4.1M
CLLKF
Sector
Market Cap
$155.9M
$28.5M
Price % of 52-Week High
52.48%
51.43%
Dividend Yield
0%
0%
Shareholder Yield
6.66%
-1.33%
1-Year Price Total Return
-21.24%
-21.18%
Beta (5-Year)
1.957
0.519
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $2.21
200-day SMA
Sell
Level $3.17
Bollinger Bands (100)
Sell
Level 2.09 - 3.27
Chaikin Money Flow
Buy
Level 153.8K
20-day SMA
Sell
Level $2.21
Relative Strength Index (RSI14)
Sell
Level 39.04
ADX Line
Sell
Level 21.1
Williams %R
Buy
Level -100
50-day SMA
Sell
Level $2.28
MACD (12, 26)
Sell
Level -0.03
25-day Aroon Oscillator
Sell
Level -12
On Balance Volume
Sell
Level -319K

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-0.2536)
Sell
CA Score (Annual)
Level (-0.4619)
Buy
Beneish M-Score (Annual)
Level (-2.6432)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (3.9137)
Buy
Piotroski F Score (Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)

Revenue Forecast

Earnings per Share Forecast

Company Profile

BICO Group AB engages in the provision of technologies, products, and services to create, understand, and master biology. It operates through the following segments: Bioprinting, Life Science Solutions, Lab Automation, and Group. The Bioprinting segment includes 3D bioprinters and bioinks with a wide range of technologies for different demanding applications, resolutions, and volume and speed requirements, as well as services focused on accelerating drug discovery and development with advanced tissue imaging and cell culture services. The Life Science Solutions segment supplies advanced lab instrumentation and smart workflow connectivity software to analyze data from applications in cell culture, cell imaging, cell sorting, and sample preparation for different analytics such as genomics. The Lab Automation segment offers proprietary and hardware-agnostic Green Button Go Suite software for connected and smart workflows. The Group segment is involved in the group’s administration and shareholder costs. The company was founded by Erik Paul Gatenholm and Hector Daniel Martinez Avila in March 2015 and is headquartered in Gothenburg, Sweden.

Stock Forecast FAQ

In the current month, CLLKF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CLLKF average analyst price target in the past 3 months is --.

  • Where Will BICO Group AB Stock Be In 1 Year?

    According to analysts, the consensus estimate is that BICO Group AB share price will drop to -- per share over the next 12 months.

  • What Do Analysts Say About BICO Group AB?

    Analysts are divided on their view about BICO Group AB share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BICO Group AB is a Sell and believe this share price will rise from its current level to --.

  • What Is BICO Group AB's Price Target?

    The price target for BICO Group AB over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is CLLKF A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for BICO Group AB is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of CLLKF?

    You can purchase shares of BICO Group AB via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BICO Group AB shares.

  • What Is The BICO Group AB Share Price Today?

    BICO Group AB was last trading at $2.21 per share. This represents the most recent stock quote for BICO Group AB. Yesterday, BICO Group AB closed at $2.21 per share.

  • How To Buy BICO Group AB Stock Online?

    In order to purchase BICO Group AB stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Netflix Buy Warner Bros?
Why Did Netflix Buy Warner Bros?

Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…

Why Did SoFi Stock Drop?
Why Did SoFi Stock Drop?

Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…

Will Robinhood Win AI Investing?
Will Robinhood Win AI Investing?

Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…

Stock Ideas

Buy
54
Is NVDA Stock a Buy?

Market Cap: $4.5T
P/E Ratio: 63x

Buy
56
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 37x

Buy
59
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Buy
67
GPCR alert for Dec 9

Structure Therapeutics, Inc. [GPCR] is down 2.06% over the past day.

Buy
62
SMX alert for Dec 9

SMX (Security Matters) Plc [SMX] is up 0.21% over the past day.

Buy
90
KYMR alert for Dec 9

Kymera Therapeutics, Inc. [KYMR] is down 7.99% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock